Refractory thyroid cancers;Cancers réfractaires de la thyroïde

Presse Medicale

Volumn 40, Issue 12 PART 1, 2011, Pages 1189-1198

  Schlumberger, Martin ^a   Chougnet, Cécile ^a   Baudin, éric ^a   Leboulleux, Sophie ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RADIOACTIVE IODINE; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER INCIDENCE; CANCER RESISTANCE; ENZYME INHIBITION; FRANCE; HUMAN; METASTASIS POTENTIAL; RARE DISEASE; SHORT SURVEY; SYMPTOM; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CARCINOMA; DISEASE COURSE; DRUG ANTAGONISM; DRUG RESISTANCE; EVALUATION; GENETICS; PATHOLOGY; PHYSIOLOGY; REVIEW; THYROID TUMOR; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS; TREATMENT FAILURE;

EID: 84856260368     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.09.011     Document Type: Short Survey

References (39)

1. Kloos R.T., Eng C., Evans D.B., Francis G.L., Gagel R.T., Gharib H., et al. Medullary thyroid cancer: management guidelines of the American thyroid. Thyroid 2009, 19:565-612.
2. Schlumberger M., Carlomagno F., Baudin E., Bidart J.M., Santoro M. New therapeutic approaches for medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2008, 4:22-32.
3. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
4. Schlumberger M., Sherman S.I. clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 2009, 19:1393-1400.
5. De Crevoisier R., Baudin E., Bachelot A., Leboulleux S., Travagli J.P., Caillou B., et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60:1137-1143.
6. Deandreis D., Al Ghuzlan A., Leboulleux S., Lacroix L., Garsi J.P., Talbot M., et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptake) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocr Relat Cancer 2011, 18:159-169.
7. Ain K.B., Egorin M.J., DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000, 10:587-594.
8. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
9. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
10. 18F-fluorodeoxyglucose positron emission tomography and computerized tomography in anaplastic thyroid cancer. Eur J Nucl Med 2010, 37:2277-2285.
11. Hedinger C., Williams E.D., Sobin L.H. Histological typing of thyroid tumours, 2nd ed, No. 11. In: International histological classification of tumours. World Health Organization 1988, Springer-Verlag, New York, p. 1-20.
12. Volante M., Collini P., Nikiforov Y.E., Sakamoto A., Kakudo K., Katoh R., et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007, 31:1256-1264.
13. Fagin J.A. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004, 183:249-256.
14. Volante M., Rapa I., Gandhi M., Bussolati G., Giachino D., Papotti M., et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 2009, 94:4735-4741.
15. Wells S.A., Gosnell J.E., Gagel R.F., Moley J., Pfister D., Sosa J.A., et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28:767-772.
16. Robinson B.G., Paz-Ares L., Krebs A., Vasselli J., Haddad R. Vandetanib (100mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95:2664-2671.
17. Wells S.A., Robinson B.G., Gagel R.F., Dralle H., Fagin J.A., Santoro M., et al. Vandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial (ZETA) 2010, ITC, Paris.
18. Akeno-Stuart N., Croyle M., Knauf J.A., Malaguarnera R., Vitagliano D., Santoro M., et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 2007, 67:6956-6964.
19. Kurzrock R., Sherman S., Pfister D., Cohen R.B., Ball D., Hong D., et al. A phase I study of XL184, a RET, VEGFR2 and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) 2010, ITC, Paris.
20. Cohen E.E.W., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008, 26:4708-4713.
21. Schlumberger M., Elisei R., Bastholt L., Wirth L.J., Martins R.G., Licitra L., et al. Phase II study of safety and efficacy of motesanib (AMG 706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009, 27:3794-3801.
22. Lam E.T., Ringel M.D., Kloos R.T., Prior T.W., Knopp M.V., Liang J., et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010, 28:2323-2330.
23. Carr L.L., Mankoff D.A., Goulart B.H., Eaton K.D., Capell P.T., Kell E.M., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16:5260-5268.
24. Busaidy N., De Souza J.A., Zimrin A., Seiwert T.Y., Villafor V.M., Poluru K., et al. Sunitinib in progressive metastatic medullary thyroid cancer 2010, ITC, Paris.
25. Ravaud A., de la Fouchardière C., Courbon F., et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 2008, 26. (Abstract ASCO).
26. Nemunaitis J.J., Senzer N.N., Kurzrock R., Ng C.S., Das A., Atienza R.S., et al. Phase I dose escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008, 26(abst. 14583):634s.
27. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., et al. Phase II trial of Sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719.
28. Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684.
29. Hoftijzer H., Heemstra K., Morreau H., Stokkel M.P., Corssmit E.P., Gelderblom H., et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009, 161:923-931.
30. Waguespack S.G., Sherman S.I., Williams M.D., Clayman G.L., Herzog C.E. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 2009, 19:407-412.
31. Bible K.C., Suman V.J., Molina J.R., Smallridge R.C., Maples W.J., Menefee M.E., et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010, 11:962-972.
32. Sherman S.I., Wirth L.J., Droz J.P., Hofmann M., Bastholt L., Martins R.G., et al. Motesanib diphosphate in progressive, differentiated thyroid cancer. N Engl J Med 2008, 359:31-42.
33. Cohen E.E.W., Needles B.M., Cullen K.J., Wong S., Wade J., Ivy P., et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008, 26:6025. [meeting abstract].
34. Leboulleux S., Bastholt L., Krause T.M., de la Fouchardière C., Tennvall J., Awada A., et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind phase II trial 2010, ITC, Paris.
35. Flaherty K., Puzanov I., Sosman J., Kim K., Ribas A., McArthur G., et al. Phase I study of PLX4032: proof of concept for V600EBRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009, 27:9000. [meeting abstract].
36. Nemunaitis J.J., et al. Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008, 26:14583. [meeting abstract].
37. Mooney C.J., Nagaiah G., Fu P., Wasman J.K., Cooney M.M., Savvides P.S., et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009, 19:233-240.
38. Magnon C., Opolon P., Ricard M., Connault E., Ardouin P., Galaup A., et al. Radiation and angiogenesis inhibition by Canstatin synergize to induce HIF-1-mediated tumor apoptotic switch. J Clin Invest 2007, 117:1844-1855.
39. Francis Z., Baudin E., Leboulleux S., Schlumberger M. Angiogenèse et cancer de la thyroïde. Presse Med 2009, 38:1641-1646.